HCW Biologics Inc. (HCWB) Stock

NASDAQ: HCWBDevelops biologics for immune modulation and cancer immunotherapy, focusing on novel approaches to enhance patient outcomes.

HCW Biologics stock price chart

HCWB interactive chart →

HCWB stock quote & key statistics

HCW Biologics earnings per share

Income →

Earnings per share

HCW Biologics revenue & net income

Income →

RevenueNet income

HCW Biologics annual financials

Income statement →

HCW Biologics Inc. revenue, net income and EPS by fiscal year
Fiscal year	Revenue	Net income	EPS
FY2025	$54,232	-$8.0M	-$25.08
FY2024	$2.6M	-$30.0M	-$211.20
FY2023	$2.8M	-$25.0M	-$62.84
FY2022	$6.7M	-$14.9M	-$100.80
FY2021	$4.1M	-$12.9M	-$1.11

Fiscal year ending December 31. Source: company filings via EODHD.

About HCW Biologics Inc.

HCW Biologics Inc. is a biopharmaceutical company in the preclinical stage, specializing in the discovery and development of innovative immunotherapies targeting chronic, low-grade inflammation, and age-related diseases.

The company's pipeline is anchored by HCW9218, an injectable immunotherapeutic designed for pancreatic, ovarian, breast, prostate, colorectal cancers, and pulmonary fibrosis. HCW Biologics also focuses on HCW9302, aimed at autoimmune conditions like alopecia areata and metabolic diseases. Additionally, the company is advancing HCW9201, a cell-based therapy currently in Phase II clinical trials for relapsed/refractory acute myeloid leukemia, and HCW9206 for acute myeloid leukemia treatment.

Founded in 2018 and headquartered in Miramar, Florida, HCW Biologics Inc. is committed to pioneering therapies that address significant medical needs. The company's innovative approach and clinical advancements underscore its dedication to transforming treatment options for complex diseases.

HCW Biologics stock FAQ

What is the HCW Biologics stock ticker symbol?

HCW Biologics Inc. trades on the NASDAQ under the ticker symbol HCWB.

What sector and industry is HCW Biologics in?

HCW Biologics Inc. is classified in the Healthcare sector, Biotechnology industry.

How many employees does HCW Biologics have?

HCW Biologics Inc. has about 35 full-time employees.

What were HCW Biologics's revenue and earnings last fiscal year?

HCW Biologics reported revenue of $54,232 and net income of -$8.0M in fiscal 2025, with earnings per share of -$25.08. Revenue declined 97.9% from the prior year.

When did HCW Biologics go public?

HCW Biologics stock began trading on July 20, 2021.

Biotechnology stocks

All Healthcare stocks →